This Health Care Software Firm Nears Buy Point After Whopping 101% Year-To-Date Gain
- Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point.
- 12/20/2024
|
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.
- 12/19/2024
|
Doximity initiated with an Equal Weight at Stephens
- Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, though it has "settled into a low-to-mid-teens growth profile," the analyst tells investors. The firm believes the current valuation presumes revenue growth will re-accelerate based on the self-serve marketplace increasing up-sell/cross-sell and new product successes and while it sees potential for EBITDA outperformance, the firm lacks "the visibility and conviction to model above-consensus growth and further margin expansion" as a base case, the analyst tells investors.
- 12/19/2024
|
Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician telemedicine users surveyed would like virtual care to remain a permanent part of their clinical practice. Among physicians surveyed, 84% highlighted telemedicine's value in improving continuity of care for patients with chronic or complex conditions, and 96% emphasized its role as a complement to.
- 12/17/2024
|
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025
- The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.
- 12/16/2024
|
Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
- Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financials, with earnings surpassing expectations, strong cash reserves, and high margins, indicating robust scalability and efficiency. New AI-powered features and product launches enhance clinical workflows, while leadership's proven track record supports continued market expansion and service broadening.
- 12/06/2024
|
Buy 5 High-Flying Health & Fitness Stocks of 2024 With More Upside
- Five Health & Fitness stocks have strong growth potential for 2025. These are GRMN, SFM, DOCS, PLNT and PTON.
- 12/05/2024
|
Doximity initiated with a Neutral at Mizuho
- Mizuho initiated coverage of Doximity with a Neutral rating and $55 price target. The company has witnessed some volatility in quarterly top-line growth over the past few years due to timing of pharma digital ad spending within the Doximity physician user app, including decelerating top-line growth throughout much of FY24, the analyst tells investors in a research note. Mizuho adds that it remains confident in Doximity's ability to generate low double-digit annual revenue growth over the next few years, but also believes that there may be better entry points into the stock.
- 12/03/2024
|
Are Medical Stocks Lagging Doximity (DOCS) This Year?
- Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.
- 12/02/2024
|
Dr Martens redemption arc will be ‘multi-year event'
- The post-IPO narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it's easy to glance over the green shoots of optimism emerging from the business. While plummeting revenues in the first half filtered through to a pre-tax loss, analysts from broker Peel Hunt noted that the numbers were broadly in line with forecasts.
- 11/28/2024
|
Dr Martens shares booted higher despite swinging to a loss
- Dr Martens PLC (LSE:DOCS)'s double-digit revenue decline and pre-tax loss in the first half wasn't as bad as it seems, if the market's reaction is anything to go by. Shares in the shoe brand, which has struggled to grow its US sales volumes, added more than 12% following publication of the results.
- 11/28/2024
|
Dr Martens delivers double-digit sales decline and jumbo pre-tax loss
- Dr Martens PLC (LSE:DOCS) had another unflattering trading performance in the first half of its financial year, with revenues declining 18% year-on-year to £325 million, in line with expectations. The iconic footwear group saw £29 million in losses before tax compared to last year's £26 million profit.
- 11/28/2024
|
Dr Martens set to unveil loss as all eyes on outlook in results
- Dr Martens PLC (LSE:DOCS)'s first half results on Thursday, 28 November will likely be more about its outlook as a decline in sales and swing to loss are expected. According to Deutsche Bank analysts, revenue is set to have fallen by 18% over the first half, pushing the shoemaker to a “well-flagged” pre-tax loss of £34 million.
- 11/27/2024
|
3 Momentum Anomaly Stocks to Buy as Election Rally Fizzles
- DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
- 11/19/2024
|
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
- Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
- 11/19/2024
|
Surging Earnings Estimates Signal Upside for Doximity (DOCS) Stock
- Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 11/15/2024
|
Doximity Q2 Earnings: Positioning Is Paying Off
- I rate Doximity a buy with a price target of $65, reflecting a 24% upside due to strong Q2 earnings and favorable industry trends. Doximity's Q2 earnings showed impressive revenue growth, margin expansion, and a revised forecast of 36% CAGR in revenue and 74% CAGR in Adjusted EBITDA. Positioned at the intersection of healthcare trends, Doximity offers cost-saving solutions that align with industry needs, supporting double-digit growth through 2030.
- 11/15/2024
|
Dr. Martens upgraded to Neutral from Sell at Goldman Sachs
- Goldman Sachs analyst Louise Singlehurst upgraded Dr. Martens to Neutral from Sell with a price target of 64 GBp, down from 71 GBp. The firm sees emerging valuation support post the recent de-rating of the shares. It expects Dr. Martens' EBIT margins to inflect positively into fiscal 2026 post three years of margin compression.
- 11/13/2024
|
Why Doximity Stock Is Skyrocketing Today
- The market loved what it saw from Doximity's second-quarter earnings.
- 11/08/2024
|
Why Doximity Stock is Set to Open at Highest Point in Over 2 Years Friday
- Doximity (DOCS) shares jumped nearly 40% in premarket trading Friday after the medical tech company's earnings and outlook came in above what analysts expected.
- 11/08/2024
|
Doximity Stock Soars 42% Toward Best Day Ever. It's Not the Only Record.
- The online medical platform reported quarterly revenue of $136.8 million and earnings of 30 cents a share, beating analysts expectations.
- 11/08/2024
|
Doximity, Inc. (DOCS) Q2 2025 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Perry Gold - Vice President of Investor Relations Jeff Tangney - Co-Founder and CEO Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder and Chief Strategy Officer Conference Call Participants Glen Santangelo - Jefferies Johnathan McCary - Raymond James Stephanie Davis - Barclays Jared Haase - William Blair Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Dan Clark - Leerink Scott Schoenhaus - KeyBanc Scott Berg - Needham & Company Jailendra Singh - Truist Eric Percher - Nephron John Park - Morgan Stanley Operator Well, good day, everyone, and welcome to the Doximity Fiscal 2Q '25 Earnings Call. At this time, I would like to hand the call over to Mr.
- 11/07/2024
|
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
- Doximity (DOCS) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.22 per share a year ago.
- 11/07/2024
|
Morgan Stanley Upbeat On This Telehealth Stock; 80% Of Doctors Use It
- This telehealth technology provider is holding above its 50-day moving average. The company reports its next earnings on Nov. 7.
- 10/31/2024
|
Doximity (DOCS) Outperforms Broader Market: What You Need to Know
- Doximity (DOCS) closed at $41.88 in the latest trading session, marking a +1.11% move from the prior day.
- 10/29/2024
|
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- In the most recent trading session, Doximity (DOCS) closed at $41.42, indicating a -1.76% shift from the previous trading day.
- 10/23/2024
|
Doximity to Release Fiscal 2025 Second Quarter Results on November 7, 2024
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/.
- 10/17/2024
|
3 Medical Services Stocks to Buy to Navigate Industry Challenges
- The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most.
- 10/17/2024
|
Overlooked Stock: DOCS
- Doximity (DOCS) is trading near its 52-week high after getting an upgrade from Barclays. George Tsilis talks about why the "LinkedIn for physicians" can be gaining investor interest.
- 10/15/2024
|
DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS
- NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Doximity, Inc. (“Doximity”) (NYSE: DOCS) breached their fiduciary duties to Doximity and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Doximity's board of directors or senior management failed to manage Doximity in an acceptable manner, in breach of their fiduciary dut.
- 10/07/2024
|
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.
- 09/25/2024
|
Top 4 Health Care Stocks That May Keep You Up At Night
- As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
- 09/24/2024
|
Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
- Doximity (DOCS) reachead $40.88 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.
- 09/20/2024
|
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.
- 09/16/2024
|
SOLV vs. DOCS: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
- 09/16/2024
|
LTH vs. DOCS: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical Services sector have probably already heard of Life Time Group Holdings, Inc. (LTH) and Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?
- 08/28/2024
|
Should You Buy This Stock After It Skyrocketed by 33%?
- Doximity recently reported strong financial results. The company has solid growth opportunities.
- 08/25/2024
|
Reconsidering Doximity Shares: Should Investors Bet On A Sustained Revenue Growth Inflection
- Doximity's guidance in no way reflects the positive tea leaves management discussed during the conference call. Doximity reported better than expected Q1 results with revenues of $127 million and adjusted EBITDA of $66 million, leading to a 39% increase in share price. The company minimally increased its adjusted EBITDA forecast for FY '25, but potential for sustainable growth rates is not reflected in consensus estimates.
- 08/23/2024
|
Doximity: The 'Facebook for Doctors' Surges After Earnings Beat
- Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research.
- 08/21/2024
|
LTH vs. DOCS: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical Services stocks have likely encountered both Life Time Group Holdings, Inc. (LTH) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?
- 08/12/2024
|
Doximity: Q1 Earnings Mark A Possible Turnaround For The Company (Rating Upgrade)
- Doximity reported strong Q1 FY25 earnings with revenue and Adjusted EBITDA growing 17% and 41% YoY respectively, beating estimates. It saw a 16% increase in customer count in its $500K+ Subscription revenue cohort, while usage of its products continued to grow steadily, alongside expanding margins. Although the management sounded cautious on the state of the economy, it believes that its product innovation should help it capture larger pharma budgets in the coming years.
- 08/09/2024
|
Why Doximity Stock Was Soaring Today
- Doximity beat estimates on the top and bottom lines. The company continues to report strong margins.
- 08/09/2024
|
Why Is Doximity (DOCS) Stock Up 30% Today?
- Doximity (NYSE: DOCS ) stock is rising higher on Friday following the release of the medical cloud-based digital platform company's earnings report for its fiscal first quarter of 2025. That earnings report starts off strong with adjusted EPS of 28 cents per share.
- 08/09/2024
|
Doximity Stock Jumps 31%. Here's Why.
- The medical platform's quarterly result beat expectations on both top and bottom lines, and is also leveraging AI to appeal to customers.
- 08/09/2024
|
Doximity, Inc. (DOCS) Q1 2025 Earnings Call Transcript
- Start Time: 17:00 January 1, 0000 5:50 PM ET Doximity, Inc. (NYSE:DOCS ) Q1 2025 Earnings Conference Call August 08, 2024, 17:00 PM ET Company Participants Jeff Tangney - Co-founder and CEO Nate Gross - Co-founder and CSO Anna Bryson - CFO Perry Gold - VP of IR Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Stephanie Davis - Barclays Jared Hass - William Blair John Pinney - Canaccord Genuity Allen Lutz - Bank of America Elizabeth Anderson - Evercore ISI Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Craig Hettenbach - Morgan Stanley Jenny Cao - Truist Securities Stan Berenshteyn - Wells Fargo Securities Jenny Shen - BTIG Operator Good day, everyone, and welcome to the Doximity Fiscal First Quarter 2025 Earnings Call. At this time, I would like to hand things over to Vice President of Investor Relations, Perry Gold.
- 08/08/2024
|
Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates
- Doximity (DOCS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.
- 08/08/2024
|
Gear Up for Doximity (DOCS) Q1 Earnings: Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
- 08/05/2024
|
Why the Market Dipped But Doximity (DOCS) Gained Today
- Doximity (DOCS) closed the most recent trading day at $28.66, moving +1.49% from the previous trading session.
- 07/30/2024
|
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
- The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most.
- 07/26/2024
|
Dr Martens targets growth in US direct-to-customer market
- Dr Martens PLC (LSE:DOCS) has published a bare trading update prior to a Thursday AGM. The classic British footwear company said that “trading since the start of this financial year has been in line with expectations and our guidance for (financial 2025) remains unchanged”.
- 07/11/2024
|
Doximity (DOCS) Ascends While Market Falls: Some Facts to Note
- Doximity (DOCS) closed the most recent trading day at $27.97, moving +0.5% from the previous trading session.
- 06/28/2024
|
Dr Martens rating could go either way, depending on US consumer demand - analyst
- Dr Martens PLC (LSE:DOCS) stock market rating is on something of a knife edge with analysts at Barclay's keen for visibility over the boot maker's direct-to-consumer sales channel. A less than emphatic recent trading update leaves investors guessing in regards to the company's prospects for the rest of the year.
- 06/20/2024
|
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022 to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.
- 06/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS
- NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 06/17/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 06/17/2024
|
FINAL DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/17/2024
|
DOCS DEADLINE MONDAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important June 17 Deadline in Securities Class Action – DOCS
- NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 17, 2024 lead plaintiff deadline.
- 06/14/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 06/14/2024
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Doximity, Inc. (DOCS)
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 17, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 8, 2023, Doximity released its first quarter fiscal ye.
- 06/14/2024
|
DOCS Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Doximity, Inc. (DOCS) Investors of Filing Deadline in Class Action Lawsuit
- RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States District Court for the Northern District of California.
- 06/14/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , June 13, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).
- 06/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. – DOCS
- NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
- 06/13/2024
|
DOCS Investors Have Opportunity to Join Doximity, Inc. Securities Fraud Investigation with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--DOCS Investors Have Opportunity to Join Doximity, Inc. Securities Fraud Investigation with the Schall Law Firm.
- 06/13/2024
|
Doximity, Inc. Investors: June 17, 2024 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
- SAN FRANCISCO, CA / ACCESSWIRE / June 13, 2024 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS) who suffered losses from purchasing or otherwise acquiring Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"), to contact us immediately regarding a pending securities fraud class action against Doximity. The deadline to apply to be lead plaintiff is June 17, 2024.
- 06/13/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/13/2024
|
DOXIMITY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, June 12, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District California.
- 06/12/2024
|
Rosen Law Firm Urges Doximity, Inc. (DOCS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024. Doximity describes itself as a company that “operates a digital platform that provides connections between, medical information to, and patient scheduling tools for medical professionals.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen.
- 06/12/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , June 12, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/12/2024
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Doximity
- NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) and reminds investors of the June 17, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 06/12/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/12/2024
|
DOCS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Doximity, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or “the Company”) (NYSE: DOCS) and certain of its officers.
- 06/12/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, June 11, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District California.
- 06/11/2024
|
The Schall Law Firm Urges Investors Who Have Suffered Losses With Doximity, Inc. To Make Contact. Please Keep In Mind The Deadline For This Matter
- LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/11/2024
|
Doximity, Inc. Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 06/11/2024
|
Doximity, Inc. Investors: June 17, 2024 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
- SAN FRANCISCO, CA / ACCESSWIRE / June 11, 2024 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS) who suffered losses from purchasing or otherwise acquiring Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"), to contact us immediately regarding a pending securities fraud class action against Doximity. The deadline to apply to be lead plaintiff is June 17, 2024.
- 06/11/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/11/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, LA / ACCESSWIRE / June 10, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE:DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 06/10/2024
|
Deadline in 7 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Doximity, Inc. (DOCS)
- RADNOR, Pa. , June 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 06/10/2024
|
DOXIMITY, INC. (NYSE: DOCS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Doximity, Inc.
- NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Doximity, Inc. (NYSE: DOCS)? Did you purchase your shares between February 9, 2022 and April 1, 2024, inclusive?
- 06/10/2024
|
Doximity, Inc. Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
- SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2024 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS) who suffered losses from purchasing or otherwise acquiring Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"), to contact us immediately regarding a pending securities fraud class action against Doximity. The deadline to apply to be lead plaintiff is June 17, 2024.
- 06/10/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/10/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS
- NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 06/09/2024
|
Deadline in 8 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Doximity, Inc. (DOCS)
- RADNOR, Pa., June 09, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States District Court for the Northern District of California.
- 06/09/2024
|
The Schall Law Firm Encourages Investors Who Have Incurred Losses With Doximity, Inc. To Reach Out. Please Be Conscious Of The Time Limit In This Issue
- LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/09/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/09/2024
|
The Schall Law Firm Urges Investors Who Have Suffered Losses In Doximity, Inc. To Make Contact. Please Be Mindful Of The Deadline For This Matter
- LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/08/2024
|
Deadline in 9 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Doximity, Inc. (DOCS)
- RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States Di.
- 06/08/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS , June 7, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 06/07/2024
|
The Schall Law Firm Encourages Investors Who Experienced Losses With Doximity, Inc. To Get In Touch. Please Remember The Deadline For This Issue
- LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS
- NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 06/07/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/07/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, LA / ACCESSWIRE / June 6, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE:DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 06/06/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , June 6, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Class Period: February 9, 2022 – April 1, 2024 Lead Plaintiff Deadline: June 17, 2024 If you wish to serve as lead plaintiff of the Doximity lawsuit, you can submit your contact information at www.glancylaw.com/cases/Doximity-Inc/.
- 06/06/2024
|
DOCS INVESTOR ALERT: Kirby McInerney LLP Notifies Doximity, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
- NEW YORK--(BUSINESS WIRE)---- $docs #ClassAction--The law firm of Kirby McInerney LLP reminds investors of the June 17, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired Doximity, Inc (“Doximity” or the “Company”) (NYSE: DOCS) securities during the period of February 9, 2022 through April 1, 2024, inclusive (“the Class Period”). [Click here to learn more about the class action] On August 8, 2023, Doximity reported its financial re.
- 06/06/2024
|
The Schall Law Firm Is Urging Investors Who Have Suffered Losses In Doximity, Inc. To Reach Out. Please Be Mindful Of The Deadline In This Matter
- LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/06/2024
|
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Doximity
- NEW YORK , June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) and reminds investors of the June 17, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Doximity To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Doximity stock or options between February 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
- 06/06/2024
|
Doximity, Inc. Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
- SAN FRANCISCO, CA / ACCESSWIRE / June 6, 2024 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS) who suffered losses from purchasing or otherwise acquiring Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"), to contact us immediately regarding a pending securities fraud class action against Doximity. The deadline to apply to be lead plaintiff is June 17, 2024.
- 06/06/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/06/2024
|
DOXIMITY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District California.
- 06/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. – DOCS
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
- 06/05/2024
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Doximity, Inc. (DOCS)
- LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 17, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”).
- 06/05/2024
|
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Doximity
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) and reminds investors of the June 17, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 06/05/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/05/2024
|
DOCS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Doximity, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or “the Company”) (NYSE: DOCS) and certain of its officers.
- 06/05/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, June 04, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District California.
- 06/04/2024
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important June 17 Deadline in Securities Class Action – DOCS
- NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 17, 2024 lead plaintiff deadline.
- 06/04/2024
|
IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES , June 4, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/04/2024
|
Doximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, PA / ACCESSWIRE / June 4, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE:DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action, captioned Kissler v.
- 06/04/2024
|
DOCS CRUCIAL DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/04/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- BENSALEM, Pa. , June 4, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 06/04/2024
|
Doximity, Inc. Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
- SAN FRANCISCO, CA / ACCESSWIRE / June 4, 2024 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS) who suffered losses from purchasing or otherwise acquiring Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"), to contact us immediately regarding a pending securities fraud class action against Doximity. The deadline to apply to be lead plaintiff is June 17, 2024.
- 06/04/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/04/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, LA / ACCESSWIRE / June 3, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE:DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 06/03/2024
|
Doximity, Inc. Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 06/03/2024
|
NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Doximity, Inc.
- RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States District Court for the Northern District of California. Important Deadline Reminder: Investors who purchased or otherwise acquired Doximity common stock during the Class Period may, no later than June 17, 2024, move the Court to serve as lead plaintiff for the class.
- 06/03/2024
|
Doximity, Inc. Investors: June 17, 2024 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
- SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2024 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS) who suffered losses from purchasing or otherwise acquiring Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"), to contact us immediately regarding a pending securities fraud class action against Doximity. The deadline to apply to be lead plaintiff is June 17, 2024.
- 06/03/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/03/2024
|
CRUCIAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/02/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / June 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 06/02/2024
|
NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Doximity, Inc.
- RADNOR, PA / ACCESSWIRE / June 1, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE:DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action, captioned Kissler v.
- 06/01/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS
- NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 06/01/2024
|
IMPORTANT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 06/01/2024
|
DOXIMITY SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS , May 31, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District California.
- 05/31/2024
|
Class Action Announcement for Doximity, Inc. (DOCS): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Doximity, Inc.
- RADNOR, Pa. , May 31, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/31/2024
|
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/31/2024
|
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Doximity
- NEW YORK , May 31, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) and reminds investors of the June 17, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Doximity To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Doximity stock or options between February 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
- 05/31/2024
|
IMMINENT DOCS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Doximity, Inc. Investors to Join the Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Doximity securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period").
- 05/31/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE:DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/30/2024
|
ROSEN, A LONGSTANDING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
- NEW YORK , May 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/30/2024
|
Doximity to Present at the William Blair 44th Annual Growth Stock Conference
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024 at 2:00 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties.
- 05/30/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , May 30, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).
- 05/30/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS
- NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 05/30/2024
|
NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Files a Securities Class Action Lawsuit Against Doximity, Inc.
- RADNOR, PA / ACCESSWIRE / May 30, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE:DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action, captioned Kissler v.
- 05/30/2024
|
Dr Martens' sales nosedive, British footwear brand struggles to capture US market
- Iconic British footwear brand Dr Martens PLC (LSE:DOCS) posted expectedly poor full-year results this Thursday, with revenues coming in even worse than initially expected. Revenues of £877.1 million represented a year-on-year decrease of 12.3%, undershooting the 11% drop forecasted by the market.
- 05/30/2024
|
Doximity (DOCS) Upgraded to Buy: Here's What You Should Know
- Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/29/2024
|
NYSE: DOCS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Doximity, Inc.
- RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281-JST was filed in the United States Di.
- 05/27/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS , May 24, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/24/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES , May 24, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/24/2024
|
Dr Martens' results to clarify on outlook as bad streak persists
- Dr Martens PLC (LSE:DOCS) is expected to report a hefty drop in profit when full-year results come out on Thursday, May 30. This is as the bootmaker nurses heavy losses in the US on falling wholesale revenue.
- 05/24/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , May 23, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Class Period: February 9, 2022 – April 1, 2024 Lead Plaintiff Deadline: June 17, 2024 If you wish to serve as lead plaintiff of the Doximity lawsuit, you can submit your contact information at www.glancylaw.com/cases/Doximity-Inc/.
- 05/23/2024
|
Doximity Releases New Study on Physician Compensation, Overwork, and Shortage
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2024 Physician Compensation Report. The report reveals that the average pay for doctors increased 5.9% in 2023 after a decline of 2.4% the previous year. The report also points to a 23% gender wage gap, with men physicians earning nearly $102,000 more than women physicians, even when controlling for specialty, location, and years of experience. The report.
- 05/23/2024
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
- New York , May 22, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/22/2024
|
Doximity is the Facebook and LinkedIn of the Medical Community
- Doximity Inc. NASDAQ: DOCS is a social networking platform exclusively designed for U.S. healthcare professionals. It's a cross between Meta Platforms Inc. NASDAQ: META owned Facebook and Microsoft Co. NASDAQ: MSFT owned LinkedIn.
- 05/22/2024
|
DOCS INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
- NEW YORK--(BUSINESS WIRE)---- $DOCS #DOCS--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 17, 2024 lead plaintiff deadline. SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D.
- 05/21/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- BENSALEM, Pa. , May 21, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 05/21/2024
|
Doximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, Pa. , May 20, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/20/2024
|
Company News for May 20, 2024
- Shares of RBC Bearings Incorporated ((RBC Quick QuoteRBC - Free Report) ) jumped 8.1% after the company reported fourth-quarter fiscal 2024 earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.32 per share.Flowers Foods, Inc.’s ((FLO Quick QuoteFLO - Free Report) ) shares declined 4.1% after the company reported first-quarter fiscal 2024 earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.40 per share.Shares of Doximity, Inc. ((DOCS Quick QuoteDOCS - Free Report) ) soared 18.1% after the company reported fourth-quarter fiscal 2024 earnings of $0.25 per share, surpassing the Zacks Consensus Estimate of $0.20 per share.GameStop Corp.’s ((GME Quick QuoteGME - Free Report) ) shares plunged 19.7% after the company announced that it plans to sell 45 million common stocks in shares. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
- 05/20/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/19/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/18/2024
|
DOXIMITY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS , May 17, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District California.
- 05/17/2024
|
Doximity Surges on Earnings Beat, Strong Outlook, Stock Buyback Announcement
- Shares in Doximity (DOCS) surged Friday after the digital medical networking company announced earnings that beat Wall Street estimates, provided a better-than-expected current-quarter outlook, and unveiled a share buyback program.
- 05/17/2024
|
Why Doximity Stock Is Skyrocketing Today
- Doximity beat revenue and earnings estimates with its fiscal Q4 results. The company's guidance projects solid growth.
- 05/17/2024
|
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/17/2024
|
‘An AI-fueled equity bubble' will see big tech lead the charge in coming months
- Early Friday futures action shows stocks opening little changed after easing fractionally back from record highs in the previous session.
- 05/17/2024
|
Doximity, Inc. (DOCS) Q4 2024 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q4 2024 Earnings Conference Call May 16, 2024 5:00 PM ET Company Participants Perry Gold - Vice President Investor Relations Jeff Tangney - Co-Founder and Chief Executive Officer Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder and Chief Strategy Officer Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Jared Hass - William Blair Richard Close - Canaccord Genuity Glen Santangelo - Jefferies Elizabeth Anderson - Evercore ISI Dan Clark - Leerink Partners Anne Samuel - JPMorgan Stan Berenshteyn - Wells Fargo Securities Stephanie Davis - Barclays Jack Wallace - Guggenheim Securities Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Scott Schoenhaus - KeyBanc Craig Hettenbach - Morgan Stanley Operator Thank you for standing by. My name is Greg and I will be your conference operator today.
- 05/16/2024
|
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
- Doximity (DOCS) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.
- 05/16/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , May 16, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).
- 05/16/2024
|
Doximity Announces Fourth Quarter and Fiscal Year 2024 Financial Results
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 fourth quarter and fiscal year ended March 31, 2024. “We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “We're proud to bring AI and automation to clinical workflows, with over 580,000 unique providers usin.
- 05/16/2024
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
- NEW YORK , May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/15/2024
|
Doximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, Pa. , May 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/15/2024
|
Kirby McInerney LLP Reminds Doximity, Inc. (DOCS) Investors of Class Action Filing and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Doximity, Inc (“Doximity” or the “Company”) (NYSE: DOCS) securities during the period of February 9, 2022 through April 1, 2024, inclusive (“the Class Period”). Investors have until June 17, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click h.
- 05/15/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES , May 15, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/15/2024
|
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/15/2024
|
2 No-Brainer Growth Stocks Down 29% and 22% to Buy Hand Over Fist Right Now
- Healthcare and beauty spending tend to be resilient in a wide range of economic environments. Doximity's platform capitalizes on essential needs in the healthcare industry, while generating most of its money from subscriptions for advertising, recruitment solutions, and other services.
- 05/14/2024
|
Ahead of Doximity (DOCS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 05/13/2024
|
Dr Martens profits to face pressure in coming years, says analyst
- Dr Martens PLC (LSE:DOCS) investors will need to brace for lower earnings and a subdued share price over the next few years as it continues its shift to a direct-to-consumer model, analysts believe. Barclays cut its earnings per share forecasts by 56% for the 2025 financial year and by 46% for the year after, following the retailer's recent profit warning.
- 05/13/2024
|
DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS , May 11, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/11/2024
|
Dr Martens confirms early start date for finance chief
- Dr Martens PLC (LSE:DOCS), the shoe manufacturer, confirmed its newly appointed chief finance officer will join the company two weeks earlier than forecast. Giles Wilson was initially set to take up his role on 27 May 2024, but will now start of Monday, May 13 2024.
- 05/10/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- LOS ANGELES , May 9, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Class Period: February 9, 2022 – April 1, 2024 Lead Plaintiff Deadline: June 17, 2024 If you wish to serve as lead plaintiff of the Doximity lawsuit, you can submit your contact information at www.glancylaw.com/cases/Doximity-Inc/.
- 05/09/2024
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
- NEW YORK , May 8, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 17, 2024 lead plaintiff deadline . SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/08/2024
|
Doximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, Pa. , May 8, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").
- 05/08/2024
|
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit
- BENSALEM, Pa. , May 7, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 05/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS
- NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 05/06/2024
|
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 17, 2024.
- 05/05/2024
|
DOXIMITY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS
- NEW ORLEANS, May 3, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against Doximity, Inc. (NYSE: DOCS), if they purchased or otherwise acquired the Company's shares between February 9, 2022, and April 1, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District California.
- 05/03/2024
|
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Doximity
- NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) and reminds investors of the June 17, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Doximity To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Doximity stock or options between February 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
- 05/03/2024
|
3 Medical Services Industry Stocks to Buy as Nursing Market Booms
- The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most.
- 04/25/2024
|
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
- 04/11/2024
|
Down -6.99% in 4 Weeks, Here's Why You Should You Buy the Dip in Doximity (DOCS)
- The heavy selling pressure might have exhausted for Doximity (DOCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 04/03/2024
|
All You Need to Know About Doximity (DOCS) Rating Upgrade to Buy
- Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/28/2024
|
ICLR vs. DOCS: Which Stock Is the Better Value Option?
- Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
- 03/14/2024
|
1 Cash-Gushing Stock Down 70% to Buy and Hold Forever
- Doximity's stock is down over 70% from its all-time highs. However, its sales have more than doubled since its 2021 initial public offering.
- 02/21/2024
|
Doximity, Inc. (DOCS) Q3 2024 Earnings Call Transcript
- Doximity, Inc. (DOCS) Q3 2024 Earnings Call Transcript
- 02/08/2024
|
Compared to Estimates, Doximity (DOCS) Q3 Earnings: A Look at Key Metrics
- The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/08/2024
|
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates
- Doximity (DOCS) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.22 per share a year ago.
- 02/08/2024
|
Countdown to Doximity (DOCS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 02/06/2024
|
3 Stocks to Capitalize on the Telehealth Explosion
- The COVID-19 pandemic highlighted the sometimes fragile nature of the American healthcare system. Many people had to delay elective surgeries and forego other treatments for an extended period.
- 01/08/2024
|
Doximity raised to ‘Neutral' as analysts see limited downside amidst macro challenges
- Doximity Inc is well-positioned to meet and exceed expectations for fiscal 2024 after the online networking service for medical professionals cut its guidance and messaged slower growth, according to analysts at Bank of America. With "no more shoes to drop," the analysts have upgraded the stock to 'Neutral' from 'Underperform' and lifted their price objective to $29 from $21.
- 01/02/2024
|
Doximity (DOCS) Upgraded to Buy: What Does It Mean for the Stock?
- Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/29/2023
|
7 Stocks that Multiple AI Bots Predict Will Soar in the Near Future
- AI stock predictions are all the rage, and for good reason. I asked Google's Bard and ChatGPT to give me some predictions regarding which stocks will soar soon.
- 12/29/2023
|
The Top Healthcare Stocks to Buy With $100
- Pfizer has important, ongoing projects that should start to pay off down the road. Doximity's strong margins, moat, and growth opportunities could mean a bright future.
- 12/21/2023
|
Future in Fitness: 3 Stocks Innovating in Digital Health
- Digital health and telemedicine are booming sectors offering attractive opportunities to investors looking to capitalize on the growing demand for remote healthcare. A couple of years ago, the Covid-19 pandemic accelerated the adoption of digital health solutions such as online consultations, remote monitoring, and digital prescriptions.
- 12/10/2023
|
5 Telehealth Stocks That Have Nothing But Upside
- The telehealth sector is undergoing a significant transformation, reshaping the traditional contours of medical service delivery. This innovation-driven domain is drawing attention from investors, as top telehealth stocks show potential in a rapidly expanding market.
- 11/26/2023
|
Earnings Estimates Moving Higher for Doximity (DOCS): Time to Buy?
- Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 11/24/2023
|
Top 3 Telehealth Stocks to Invest in for a Future of Virtual Care
- Telehealth stocks were all the rage during the pandemic, with many expecting the valuations of these companies to soar due to people staying home and practicing social distancing. However, as the old normal returned, some investors cast doubt over the long-term viability of telehealth stocks.
- 11/14/2023
|
ICLR or DOCS: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?
- 11/10/2023
|
Doximity Stock Rallies. Guidance Boost 'Just What the Doctor Ordered.
- The online platform for medical professionals also reported fiscal second-quarter adjusted earnings that beat analysts' estimates.
- 11/10/2023
|
Doximity, Inc. (DOCS) Q2 2024 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q2 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Perry Gold - VP of IR Jeffrey Tangney - Co-Founder & CEO Anna Bryson - CFO Nate Gross - Co-Founder & CSO Conference Call Participants Brian Peterson - Raymond James Richard Close - Canaccord Genuity Ryan Daniels - William Blair Scott Berg - Needham & Company Samir Patel - Evercore ISI Jessica Tassan - Piper Sandler Scott Schoenhaus - KeyBanc Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Allen Lutz - Bank of America Glen Santangelo - Jefferies David Larsen - BTIG Operator Good afternoon. My name is Krista and I'll be your conference operator today.
- 11/09/2023
|
Doximity (DOCS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/09/2023
|
Doctors have a new way to scrub personal information from internet after spike in harassment
- Doximity announced a free new service called DocDefender that can remove a physician's personal phone numbers and addresses from public websites
- 11/01/2023
|
The Top Healthcare Stocks to Buy With $100
- Doximity has several things going its way, including its economic moat, high margins, and growth opportunities. Teladoc Health shares continue to fall even as the company has made tremendous progress in recent years.
- 10/28/2023
|
MD or DOCS: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
- 10/03/2023
|
1 Growth Stock Down 39% to Buy and Hold for 10 Years
- Doximity's valuation and slowing sales growth are turning off many investors. Despite these issues, there is a lot to like about the company, including its moat.
- 09/25/2023
|
3 Top Stocks That Just Went on Sale
- Enphase is the cheapest it has ever been on a free-cash-flow basis. Toro hopes to restart sales growth, armed with a new Lowe's partnership.
- 09/24/2023
|
1 Growth Stock Down Nearly 40% to Buy and Hold For 10 Years
- Doximity is profitable and boasts high gross and net margins. The company's platform displays the flywheel effect, a powerful moat.
- 08/16/2023
|
Down 39.9%, Is Doximity a Buy on the Dip?
- Doximity shares recently fell in response to a revised forward outlook management shared during its fiscal first-quarter earnings report. Over half a million unique U.S. physicians used Doximity's digital workflow tools during the three months ended June 30.
- 08/14/2023
|
Time to Cut and Run on This 1 Formerly Promising Digital Health Stock?
- Doximity's revised guidance for the current fiscal year was horrendous. The business is still growing a bit and is highly profitable.
- 08/12/2023
|
Why Doximity Stock Plunged 29% This Week
- Doximity announced solid fiscal first-quarter 2024 results that exceeded expectations. But the online networking service for medical professionals is also laying off 10% of its workforce and lowered annual guidance.
- 08/11/2023
|
Why Shares of Doximity Are Falling Wednesday
- Doximity said it was trimming its workforce by 10%. The company reported increased revenue and net income.
- 08/09/2023
|
Why Is Doximity (DOCS) Stock Down 23% Today?
- Doximity (NYSE: DOCS ) stock is falling hard on Wednesday after the medical cloud services company released earnings for its fiscal first quarter of 2024. The drop in DOCS stock is despite the company reporting adjusted earnings per share of 19 cents.
- 08/09/2023
|
Doximity, Inc. (DOCS) Q1 2024 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q1 2024 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Perry Gold - VP of IR Jeffrey Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Sandy Draper - Guggenheim Securities Jared Hasson - William Blair Allen Lutz - Bank of America Jessica Tassan - Piper Sandler Elizabeth Anderson - Evercore ISI Jailendra Singh - Truist Securities David Larsen - BTIG Operator Hello, and welcome to Doximity's Fiscal First Quarter 2024 Earnings Call. I will now pass the call over to Doximity's Vice President of Investor Relations, Perry Gold.
- 08/08/2023
|
Here's What Key Metrics Tell Us About Doximity (DOCS) Q1 Earnings
- While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/08/2023
|
Doximity (DOCS) Surpasses Q1 Earnings and Revenue Estimates
- Doximity (DOCS) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
- 08/08/2023
|
ELV or DOCS: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
- 07/24/2023
|
Doximity to Release Fiscal 2024 First Quarter Results on August 8, 2023
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2023 after market close on August 8, 2023. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.
- 07/18/2023
|
4 Top Stocks to Buy in July and Hold Forever
- Doximity's massive platform for doctors is the perfect setting for healthcare advertisers. Declining fertility trends make Progyny's services all the more important to its customers.
- 07/10/2023
|
BLCO or DOCS: Which Is the Better Value Stock Right Now?
- Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?
- 07/06/2023
|
Doximity: Continue To See Positive Upside From Current Stock Level
- I recommend buying DOCS, given its benefits to the healthcare industry and pharmaceutical companies, and its potential to meet long-term revenue goals of $1 billion by FY28. DOCS should benefit from improvements in the external operating environment and its focus on the Workflow solution, which enhances its value proposition. As DOCS continue to hit guidance, the market will eventually start pricing in FY28 guidance.
- 07/04/2023
|
3 No-Brainer Growth Stocks to Buy in July and Hold for the Next Decade
- Growth stocks are up sharply this year, but there are at least a few that have been overlooked. Doximity's social media applications for physicians are more popular than ever, but the stock is down to what could be a bargain price.
- 07/04/2023
|
Doximity: Digital Health Play With Strong Fundamentals
- Doximity's recent Investor Day showcased platform enhancements and long-term financial targets, including achieving $1 billion in revenue and adjusted EBITDA margins of 45% or higher by FY28. The company plans to capture a larger share of the digital marketing landscape, expand product offerings, and deepen relationships with top customers. I am bullish on Doximity, Inc. with an end-of-year price target of $42.
- 06/21/2023
|
More Likely to 5x First: Doximity vs. Walgreens
- Doximity delivers double-digit growth -- and some of the biggest healthcare players are clients. Walgreens has invested in growing in the trillion-dollar primary care market.
- 06/14/2023
|
2 Growing Healthcare Stocks to Own for the Long Term
- Intuitive Surgical has been running higher on optimism that margins will rebound sooner than later. Doximity just shared its five-year goals, which could prove a profitable journey for shareholders.
- 06/13/2023
|
2 Magnificent Growth Stocks to Buy With $100 Right Now
- Making smaller, more frequent stock purchases is an easy way for everyday investors to avoid heavy, unexpected losses. SoFi Technologies is a member-focused digital bank that keeps growing by leaps and bounds.
- 06/09/2023
|
2 Soaring Healthcare Stocks That Could Climb Even Higher
- Shares of Veeva Systems and Doximity surged during the week ended June 2 and they're probably not finished climbing. Veeva Systems is a software-as-a-service company that caters to the biopharmaceutical industry.
- 06/05/2023
|
3 Things Investors Will Love About Doximity (and 1 They Won't)
- Doximity's networking platform is popular with healthcare professionals. That has made it easy for advertisers to target the healthcare industry.
- 06/02/2023
|
Better Healthcare AI Stock: Moderna vs. Doximity
- Moderna hopes AI will make drug discovery faster and more precise. Doximity is using AI to help doctors save time.
- 06/02/2023
|
Dr Martens tumbles as City puts boot in after margin warning
- Dr Martens PLC (LSE:DOCS) shares tumbled 11% in early exchanges as the company warned of lower margins in the year ahead alongside a 26% decline in annual pre-tax profit. The City put the boot as the inconic footwear manufacturer predicted EBITDA margins would fall by 1-2 percentage points in the financial year ahead with a 5-6 percentage point fall in the first half.
- 06/01/2023
|
Dr Martens PLC profit tumbles, margins seen lower in year ahead
- Dr Martens PLC (LSE:DOCS) revenue topped the £1bn mark for the first time but it couldn't prevent the iconic bootmaker reporting a heavy fall in profit. The FTSE 250 company posted revenue in the year to March 31 of £1.00bn, up 10% from £908.3mln, alongside a 26% decline in pre-tax profit to £159.4mln from £214.3mln.
- 06/01/2023
|
Dr Martens tumbles 6% as RBC sticks the boot in
- Dr Martens PLC (LSE:DOCS) tumbled 6.2% as broker RBC Capital Markets put the boot in ahead of the iconic shoemaker's full year results on Thursday. Shares fell to 151.30p as the broker downgraded the stock to sector perform from outperform and reduced its price target to 180p from 230p.
- 05/30/2023
|
1 No-Brainer Stock to Buy With $100 Right Now
- Doximity's productivity-boosting platform is used by over 80% of U.S. physicians and 90% of graduates. This large segment provides a lucrative advertising environment for drugmakers and hospitals.
- 05/28/2023
|
Doximity (DOCS) Reports Q4 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/26/2023
|
Doximity to Present at the William Blair 43rd Annual Growth Stock Conference
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Dr. Nate Gross, co-founder and chief strategy officer, will present at the William Blair 43rd Annual Growth Stock Conference on Thursday, June 8, 2023 at 10:00 a.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across.
- 05/23/2023
|
Doximity is an Overlooked Medical Ecosystem AI Play
- Doximity Inc. NASDAQ: DOCS is a digital professional social network platform for medical practitioners. It's a medical community networking platform like a Microsoft Co. NASDAQ: MSFT owned LinkedIn that enables doctors to communicate, interact and share information.
- 05/23/2023
|
2 Growth Stocks Billionaires Keep Buying Hand Over Fist
- Studying the activity of billionaire investors is one way to jump-start your stock-picking process. Steven Cohen's Point72 fund made a big bet on Doximity, a social media platform for physicians, in the first quarter.
- 05/18/2023
|
Doximity Stock Is Sinking. Some Bulls Aren't Budging.
- Medical platform Doximity's disappointing guidance overshadowed a strong quarterly report. Nonetheless, two analysts raised revenue outlooks.
- 05/17/2023
|
SaaS Stocks Aren't Out of the Woods Just Yet
- Stock markets looked poised to recover some of their recent losses on Wednesday morning. Wix.com shares moved higher as the website facilitator lauded its AI efforts.
- 05/17/2023
|
Doximity, Inc. (DOCS) Q4 2023 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q4 2023 Earnings Conference Call May 16, 2023 5:00 PM ET Company Participants Perry Gold - Head, IR Jeffrey Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham Richard Close - Canaccord Genuity Sandy Draper - Guggenheim Securities Ryan Daniels - William Blair Stan Berenshteyn - Wells Fargo Securities Stephanie Davis - SVB Securities Jessica Tassan - Piper Sandler Elizabeth Anderson - Evercore ISI David Larsen - BTIG Operator Hello, and welcome to Doximity's Fiscal Q4 2023 Earnings Call. I will now pass the call over to Doximity's Vice President of Investor Relations, Perry Gold, to kick off the call.
- 05/16/2023
|
Doximity (DOCS) Q4 Earnings and Revenues Top Estimates
- Doximity (DOCS) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.21 per share a year ago.
- 05/16/2023
|
3 Best Stocks to Buy in May and Hold Forever
- Teladoc looks to transition from a high-flying growth story to a profitable enterprise. Doximity's early profitability and cash generation point to incredible potential ahead.
- 05/10/2023
|
The Top 3 Artificial Intelligence Stocks to Watch
- Since ChatGPT was released last November, artificial intelligence stocks have become all the rage. As a result, every media company engaged with consumers had to have its own Chatbot.
- 04/20/2023
|
ELV or DOCS: Which Is the Better Value Stock Right Now?
- Investors interested in Medical Services stocks are likely familiar with Elevance Health (ELV) and Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
- 04/13/2023
|
ELV or DOCS: Which Is the Better Value Stock Right Now?
- ELV vs. DOCS: Which Stock Is the Better Value Option?
- 03/28/2023
|
2 Top Growth Stocks to Buy Before the Next Bull Rally
- Soaring interest rates have shares of the best and worst growth stocks under a lot of pressure. SoFi Technologies is a digital bank that trades below its book value even though it's growing by leaps and bounds.
- 03/20/2023
|
Could AI Supercharge This Growth Stock?
- Doximity is testing an AI tool that could save doctors a lot of time. The healthcare company already is a favorite of doctors, with more than 80% of them using the platform.
- 03/11/2023
|
Want $1 Million in Retirement? Invest $200,000 in These 3 Stocks and Wait a Decade
- Doximity's ability to connect physicians with pharmaceuticals and health systems is a wildly prosperous pairing. Medpace's customers could struggle in 2023, but its long-term opportunity will only grow.
- 03/11/2023
|
2 Beaten-Down Growth Stocks to Buy on the Dip
- Some of the growth stocks that were beaten mercilessly in 2022 are still trading at sensible valuations. Doximity is a social media platform viewed regularly by roughly 80% of America's physicians.
- 03/07/2023
|
Doximity Stock: Bear vs. Bull
- Doximity's earnings have climbed as it attracts more users and advertisers. But the share performance hasn't reflected the company's successes.
- 03/06/2023
|
Doximity Stock: Bull vs. Bear
- Investors haven't had any reasons to be bullish about the stock in a long time. Do they now?
- 03/03/2023
|
Doximity Is Getting In on the ChatGPT Hype
- Does this make Doximity a no-brainer buy?
- 03/01/2023
|
Here's How Much You Can Make From Investing Your Tax Return Every Year
- Doing this can strengthen your retirement plan.
- 02/27/2023
|
Is Doximity Stock a Buy Now?
- The stock has dropped 38% since its IPO.
- 02/24/2023
|
Could ChatGPT Light a Fire Beneath Doximity Stock?
- OpenAI's generative AI technology could open new opportunities for Doximity.
- 02/24/2023
|
A Bull Market Is Coming: 2 Exceptional Growth Stocks to Buy Now and Hold Forever
- These businesses dominate their rapidly growing niche markets.
- 02/21/2023
|
Better Buy: Teladoc vs. Doximity
- Both of these innovative healthcare stocks are cheap today.
- 02/21/2023
|
A Bull Market Is Coming, and This Small Healthcare Stock Could Provide Massive Growth
- Doximity downgraded guidance for its current fiscal year, but provided a rosy outlook for next year.
- 02/20/2023
|
3 Stocks Ready to Bounce Back
- These stocks could deliver explosive gains -- and gains that should last.
- 02/19/2023
|
Why Doximity Stock Was a Winner This Week
- For the most part, analysts remain bullish on the company, and they expressed that by raising their price targets and/or maintaining buy recommendations.
- 02/17/2023
|
2 Terrific Growth Stocks to Buy With $200 Right Now
- You don't have to be rich to get your money to start working for you.
- 02/16/2023
|
A Bull Market Is Coming: 1 Exceptional Growth Stock Down 69% to Buy and Hold Forever
- The past year has been rough on digital advertisers, but niche social media platform Doximity keeps reporting gains.
- 02/14/2023
|
Why Doximity Stock Is a Smart Buy on the Dip
- Never mind the slightly disappointing guidance revision; this company's set up for huge long-term gains.
- 02/11/2023
|
Why Doximity Stock Fell Sick on Friday
- The networking and productivity platform delivered strong results, but its guidance disappointed.
- 02/10/2023
|
Doximity, Inc. (DOCS) Q3 2023 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q3 2023 Earnings Conference Call February 9, 2023 5:00 PM ET Company Participants Perry Gold - Head of IR Jeffrey Tangney - Co-Founder & CEO Anna Bryson - CFO Nate Gross - Co-Founder & Chief Scientific Officer Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Sandy Draper - Guggenheim Stan Berenshteyn - Wells Fargo Securities Richard Close - Canaccord Genuity Ryan Daniels - William Blair Elizabeth Anderson - Evercore Jessica Tassan - Piper Sandler Stephanie Davis - SVB Securities Glen Santangelo - Jefferies Operator Hello and welcome to Doximity's Fiscal Q3 2023 Earnings Call. I will now pass the call over to Doximity's Head of Investor Relations, Perry Gold, to kick off the call.
- 02/09/2023
|
Doximity (DOCS) Surpasses Q3 Earnings and Revenue Estimates
- Doximity (DOCS) delivered earnings and revenue surprises of 29.41% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2023
|
AMN or DOCS: Which Is the Better Value Stock Right Now?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 02/06/2023
|
Why Doximity's Shares Are Up This Week
- The digital platform for physicians is due to report earnings next week.
- 02/02/2023
|
Got $3,000? 3 Growth Stocks to Double Up On Right Now
- With these growth stocks down between 25% and 38% over the last year, it may be time to add to them as they widen their moats.
- 01/20/2023
|
Doximity to Release Fiscal 2023 Third Quarter Results on February 9, 2023
- SAN FRANCISCO--( BUSINESS WIRE )--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2022 after market close on February 9, 2023. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.
- 01/19/2023
|
AMN vs. DOCS: Which Stock Is the Better Value Option?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 01/19/2023
|
Better Healthcare Buy for 2023: Medpace Holdings or Doximity?
- The healthcare stocks expect similar revenue growth in 2023.
- 01/14/2023
|
Is Doximity Stock a Buy Now?
- This company is bringing technology to healthcare, but it is unclear whether it will bring investors returns.
- 01/07/2023
|
Doximity: Ticking Many Boxes For Investors In This Environment
- Doximity is a rare IT vendor who reported positive business trends when it released its Q3 results at the start of November, 2022. The company's big pharma and hospital customers showed increased appetite for Doximity solutions.
- 01/05/2023
|
AMN or DOCS: Which Is the Better Value Stock Right Now?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 01/03/2023
|
2 Outstanding Growth Stocks to Buy Ahead of the Next Bull Market
- A bull market is coming, and these are the stocks you'll want to own when it happens.
- 12/22/2022
|
Doximity: On The Right Path To Further Consolidate Market Share
- The adoption of digital tools to increase productivity in the healthcare sector has been gradual. Doximity's product line-up caters to every link in the value chain.
- 12/22/2022
|
Could Doximity Stock Help You Become a Millionaire?
- Doximity's growth has been slowing lately, but the company still generates a ton of free cash flow.
- 12/15/2022
|
1 Growth Stock Down 65% That's a Screaming Buy Right Now
- This relatively small social media platform is eating its competitors' lunches.
- 12/11/2022
|
Here's Why Doximity Climbed 28% in November
- The telehealth company published strong earnings results and spoke favorably about its advertising business.
- 12/07/2022
|
2 Top Growth Stocks Down 65.2% to 80.3% to Buy in December
- These stocks have fallen hard in 2022, but their best days are still ahead.
- 12/05/2022
|
Why Shares of Doximity Fell This Week
- The social-media platform for healthcare professionals fell early in the week before bouncing back a bit.
- 12/01/2022
|
Doximity: There's Much To Be Excited About Here
- Doximity's shares are down more than 60% from their highs. However, the business is clearly resonating strongly with its customers, with very high ROIs.
- 11/24/2022
|
Is Doximity's Stock Still Too Expensive to Buy?
- The stock still trades at close to 50 times earnings.
- 11/23/2022
|
Why I Own Doximity Stock
- The online platform for physicians could 10x over the next 10 years.
- 11/21/2022
|
2 Unstoppable Growth Stocks to Buy Now and Hold Forever
- A topsy-turvy stock market isn't going to knock these growth stocks off of their upward-sloping paths forward.
- 11/20/2022
|
Doximity's Free Cash Flow Just More Than Doubled From a Year Ago -- Is the Stock a Buy?
- The digital platform for doctors has always focused on profitable growth, and it's really starting to pay off.
- 11/17/2022
|
Doximity Has Succeeded Where Other Advertising Stocks Couldn't
- Advertising slowdown? Tightening business budgets?
- 11/16/2022
|
AMN vs. DOCS: Which Stock Is the Better Value Option?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 11/16/2022
|
Doximity to Participate in a Fireside Chat at Raymond James Technology Investor Conference
- SAN FRANCISCO--( BUSINESS WIRE )--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Anna Bryson, CFO, will participate in a fireside chat at Raymond James Technology Investor Conference on Monday, December 5, 2022, at 10:20 a.m. Eastern Time/7:20 a.m Pacific Time.
- 11/15/2022
|
Can Doximity Stock Keep On Climbing?
- A positive earnings report recently pushed Doximity through the roof, but Investors want to know whether the stock can deliver long-term gains.
- 11/15/2022
|
Why Doximity Stock Skyrocketed Today
- The online network for doctors is returning more cash to shareholders.
- 11/11/2022
|
Doximity stock blasts off after topping second-quarter earnings estimates
- Yahoo Finance Live anchor Rachelle Akuffo reports on Doximity shares following a promising earnings beat.
- 11/11/2022
|
Why Is Doximity (DOCS) Stock Up 23% Today?
- Amid a relatively soft background in the equities sector, medical technology firm Doximity (NYSE: DOCS ), which primarily provides online networking services for medical professionals, delivered better-than-expected results for its fiscal second-quarter earnings report. As well, DOCS stock received an analyst price target bump, contributing to a 23% gain in the morning session.
- 11/11/2022
|
What made Doximity stock pop up 25% this morning?
- Doximity Inc (NYSE: DOCS) is up about 25% on Friday after the online network for medical professionals reported encouraging results for its fiscal second quarter.
- 11/11/2022
|
These 2 IPO Stocks Just Got Their Momentum Back
- After getting hit hard, these growth stocks look poised for a longer-term rebound.
- 11/11/2022
|
Doximity, Inc. (DOCS) Q2 2023 Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Perry Gold - Head of Investor Relations Jeff Tangney - Co-Founder & Chief Executive Officer Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder & Chief Scientific Officer Conference Call Participants Ryan Daniels - William Blair Brian Peterson - Raymond James Matt Shea - Needham Richard Close - Canaccord Genuity Sandy Draper - Guggenheim Cindy Motz - Goldman Sachs Stephanie Davis - SVB Leerink Stan Berenshteyn - Wells Fargo Securities Operator Hello and welcome to Doximity's Fiscal Q2 2023 Earnings Call. I will now pass the call over to Doximity's Head of Investor Relations, Perry Gold, to kick off the call.
- 11/11/2022
|
Doximity (DOCS) Beats Q2 Earnings and Revenue Estimates
- Doximity (DOCS) delivered earnings and revenue surprises of 6.25% and 2.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Why Shares of Doximity Dropped 12.4% in October
- Investors are expecting lower Doximity revenue from advertising.
- 11/07/2022
|
AMN or DOCS: Which Is the Better Value Stock Right Now?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 10/31/2022
|
Doximity to Release Fiscal 2023 Second Quarter Results on November 10, 2022
- SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its second quarter ended September 30, 2022 after market close on November 10, 2022.
- 10/20/2022
|
Which of These Bear Market Growth Stocks Is More Likely to Bounce Back?
- Both look like bargains, but only one is.
- 10/19/2022
|
3 Growth Stocks That Could Soar 62.6% to 66.3%, According to Wall Street
- Find out why analysts have such high hopes for these top growth stocks.
- 10/18/2022
|
Doximity: Fantastic Business, Current Price Point Is A Buy
- DOCS stock has been hit hard lately as the company is experiencing its first revenue growth slowdown. Management believes this is just a short-term pain due to the macro conditions and that higher growth will come back.
- 10/18/2022
|
Why Doximity (DOCS) Could Beat Earnings Estimates Again
- Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/17/2022
|
AMN vs. DOCS: Which Stock Is the Better Value Option?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 10/14/2022
|
2 High-Conviction Growth Stocks Down 51.4% and 70.9% to Buy Now and Hold Forever
- The road ahead of these fast-growing businesses is in better shape than their stock prices would suggest.
- 10/10/2022
|
Nasdaq Bear Market: 2 Top Stocks You Can Buy With $200 Right Now
- All the blood in the streets is creating opportunities for patient investors.
- 10/05/2022
|
Don't Worry About Stock-Picking Accuracy When You're Swinging for a Home Run
- Babe Ruth was the king of home runs, and also the king of strikeouts. It's OK to invest like Babe Ruth.
- 09/27/2022
|
3 Smart Tech Stocks to Buy in 2022 and Beyond
- There are deals to be had in tech for those with a long-term mindset.
- 09/23/2022
|
Doximity Stock: Bull vs. Bear
- Is this beaten-down healthcare information technology stock a buy?
- 09/15/2022
|
AMN or DOCS: Which Is the Better Value Stock Right Now?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 09/12/2022
|
Here's Why Doximity Dropped 22% in August
- The telehealth stock's growth outlook scared investors.
- 09/08/2022
|
3 Tech Stocks Down 50% or More to Buy Now
- These three companies are down big, but don't overlook their potential after crashing.
- 08/28/2022
|
AMN vs. DOCS: Which Stock Is the Better Value Option?
- AMN vs. DOCS: Which Stock Is the Better Value Option?
- 08/25/2022
|
Doximity Appears Well-Positioned But Shares May Be Fully Valued Here
- Doximity went public in June 2021, raising approximately $606 million in gross proceeds in a U.S. IPO. The firm operates a digital collaboration and communication platform for physicians in the United States.
- 08/11/2022
|
3 Healthcare Stocks With High Profit Margins
- If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
- 08/10/2022
|
BLCO vs. DOCS: Which Stock Should Value Investors Buy Now?
- BLCO vs. DOCS: Which Stock Is the Better Value Option?
- 08/09/2022
|
We were surprised by macro headwinds, seems healthcare isn't immune, says Doximity CEO
- Jeff Tangney, Doximity CEO, joins 'TechCheck' to discuss the issues with the company's quarterly earnings results, Doximity's plans for diversification and Tangney's thoughts on tele-health prospects in the future.
- 08/05/2022
|
Doximity, Inc. (DOCS) CEO Jeff Tangney on Q1 2023 Results - Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q1 2023 Results Conference Call August 4, 2022 5:00 PM ET Company Participants Perry Gold - Head, IR Jeff Tangney - Co-Founder and CEO Dr. Nate Gross - Co-Founder and CSO Anna Bryson - CFO Conference Call Participants Ryan Daniels - William Blair Scott Berg - Needham Richard Close - Canaccord Brian Peterson - Raymond James Stephanie Davis - SVB Securities Sandy Draper - Guggenheim Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Ricky Goldwasser - Morgan Stanley Operator Thank you for standing by, and welcome to Doximity Fiscal 1Q ‘23 Earnings Call. All lines have been placed on mute to prevent any background noise.
- 08/04/2022
|
3 Best Telehealth Stocks To Buy Now
- The best telehealth stocks are undervalued after an abrupt sell-off. There are a few names such as TDOC, DOCS and HUM that stand out.
- 07/19/2022
|
SVB Leerink Sees 'Cheaper Way' To Pharma Digital Marketing With This Stock
- SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX) with a buy rating and a price target of $38, implying an upside of 36%. The analysts say OptimizeRx is the largest EHR-embedded messaging network and enjoys a solid financial profile of 30%+ top-line growth.
- 07/15/2022
|
AVTR or DOCS: Which Is the Better Value Stock Right Now?
- AVTR vs. DOCS: Which Stock Is the Better Value Option?
- 07/15/2022
|
Doximity to Release Fiscal 2023 First Quarter Results on August 4, 2022
- SAN FRANCISCO , July 14, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its first quarter ended June 30, 2022 after market close on August 4, 2022. Doximity will host a conference call and webcast at 2:00 p.m.
- 07/14/2022
|
Is Doximity a Buy?
- The decline in share price may not be all that surprising given Doximity's egregious valuation last year.
- 07/14/2022
|
Doximity: A Wonderful Business At A Very Fair Price
- Doximity is the leading professional networking platform for US healthcare professionals. The company has more than 80% of US physicians on its platform.
- 07/07/2022
|
1 Under-the-Radar Growth Stock to Buy in July
- This platform for medical professionals is worth a closer look.
- 07/07/2022
|
My 3 Favorite Stocks Right Now
- These three companies are leading an internet revolution in retailing, finance, and healthcare.
- 07/07/2022
|
Pair Trade: Going Long Doximity And Short Teladoc
- The market has become much more conservative in the last few months due to inflation & recession fears. The Pandemic accelerated the transition of Telehealth.
- 07/05/2022
|
Why Doximity Stock Fell More Than 11% This Week
- Growth stocks finished off an absolutely terrible first half of the year.
- 07/03/2022
|
AVTR vs. DOCS: Which Stock Is the Better Value Option?
- AVTR vs. DOCS: Which Stock Is the Better Value Option?
- 06/29/2022
|
Doximity (DOCS) Surges 6.6%: Is This an Indication of Further Gains?
- Doximity (DOCS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 06/27/2022
|
Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High
- Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.
- 06/25/2022
|
2 Top Healthcare Stocks Near 52-Week Lows to Buy
- These two businesses are stronger than ever, but their stock prices are at their lowest points in at least a year.
- 06/19/2022
|
Doximity Stock is an Interesting Healthcare Play
- Cloud-based healthcare community platform Doximity (NASDAQ: DOCS) stock may be put in a bottom as its trades down (-35%) for the year.
- 06/13/2022
|
3 Growth Stocks I'm Ready to Buy If the Market Crashes in June
- Buying the right beaten-down stocks this summer could supercharge your portfolio for years to come.
- 06/02/2022
|
2 Growth Stocks to Buy Before the Market Rebounds
- The market will inevitably bounce back, and these two stocks could help lead the recovery.
- 05/30/2022
|
6 Top Insider Buys of the Week
- Tracking insider buying allows retail investors to take a look at how insiders view their company. This week, the list includes COIN and CVNA stocks.
- 05/27/2022
|
Tech Stock Sell-Off Got You Scared? Here's a Better Buy.
- Doximity is a hot buy for 2022.
- 05/21/2022
|
Broken Growth Stocks: Doximity
- The fifth article in our Broken Growth series focuses on a founder-led company. Doximity is a targeted social media platform with approximately 80% of all U.S. providers, including doctors, nurse practitioners and physician assistants.
- 05/21/2022
|
Why Doximity Stock Dropped Today
- Investors might have overreacted to an expected near-term revenue decline.
- 05/18/2022
|
Final Trades: Progressive, Doximity, BHP & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 05/18/2022
|
Why Doximity Stock Is Falling Today
- Doximity Inc (NYSE: DOCS) shares are trading lower Wednesday after the company reported financial results and issued quarterly guidance below analyst estimates. Doximity said fiscal fourth-quarter revenue increased 40% year-over-year to $93.7 million, which beat the $90.11-million estimate,.
- 05/18/2022
|
Doximity, Inc. (DOCS) CEO Jeff Tangney on Q4 2022 Results - Earnings Call Transcript
- Doximity, Inc. (NYSE:DOCS ) Q4 2022 Earnings Conference Call May 17, 2022 5:00 PM ET Company Participants Perry Gold - Head, Investor Relations Jeff Tangney - Co-Founder and Chief Executive Officer Nate Gross - Co-Founder and Chief Scientific Officer Anna Bryson - Chief Financial Officer Conference Call Participants Stephanie Davis - SVB Securities Ryan Daniels - William Blair Glen Santangelo - Jefferies Brian Peterson - Raymond James Matt Shea - Needham Cindy Motz - Goldman Sachs Richard Close - Canaccord Genuity Sandy Draper - Guggenheim Jessica Tassan - Piper Sandler Operator Ladies and gentlemen, thank you for standing by and welcome to Doximity's Fourth Quarter Fiscal 2022 Earnings Call. [Operator Instructions] Thank you.
- 05/17/2022
|
Earnings Results: Doximity stock plummets after forecast, heads lower than IPO price for first time
- Doximity Inc. shares plunged toward all-time lows in after-hours trading Tuesday, following an earnings report that projected an unexpected revenue decline in the current quarter.
- 05/17/2022
|
Earnings Preview: What To Expect From Doximity On Tuesday
- Doximity Inc. is scheduled to report earnings after Tuesday's close. Here's a closer look.
- 05/17/2022
|
Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?
- Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.
- 05/16/2022
|
My Favorite Biotech
- Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.
- 05/13/2022
|
4 Stocks That Could Turn $10,000 Into $200,000 by 2040
- If you have a long investing time horizon, these strong performers could deliver massive gains.
- 04/28/2022
|
3 Stocks That Could Turn $200,000 Into $1 Million by 2032
- These companies strike the right balance of potential and leadership, which could help them achieve strong returns over the next decade.
- 04/18/2022
|
1 Unique Business to Buy and Hold for the Next 3 Years
- Doximity's revolutionary business model creates a compelling competitive advantage for the company.
- 04/13/2022
|
These Ridiculously Cheap Stocks Are Obvious Winners
- The market has put these stocks on sale.
- 04/09/2022
|
2 Outstanding Healthcare Companies With Huge Potential
- Is Doximity or Teladoc the better investment right now?
- 04/09/2022
|
Why Doximity Stock Slumped 15% in March
- Doximity's high valuation hurt the stock even though it didn't publish any bad news in March.
- 04/05/2022
|
2 TeleHealth Stocks to Buy, 1 to Watch in 2022
- Patient care via phone and video is far from finished.
- 04/02/2022
|
3 Best Telemedicine Stocks for Investors
- What's a break in the clouds due to the pandemic? Maybe the ease of meeting with your doctor.
- 04/02/2022
|
Doximity: Turning Bullish After Stock Price Correction
- Doximity (DOCS) is a high-quality company which we previously covered. At the time we came to the conclusion shares were too expensive.
- 04/01/2022
|
OCDX vs. DOCS: Which Stock Is the Better Value Option?
- OCDX vs. DOCS: Which Stock Is the Better Value Option?
- 04/01/2022
|
3 Unstoppable Stocks You Can Buy Right Now for Less Than $100
- This market provides plenty of opportunities for great deals.
- 03/24/2022
|
Why Shopify, Doximity, and Datadog Stock Fell Today
- Investors are anticipating a Federal Reserve rate hike this week.
- 03/14/2022
|
2 Stocks I Will Buy If the Stock Market Keeps Crashing
- With prices on many stocks dropping like stones, these two companies are near the top of my "to buy" watchlist.
- 03/12/2022
|
3 Biotechs That Will Crush the Bear
- Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.
- 03/11/2022
|
Why Doximity Stock Soared Nearly 8% Today
- Healthcare is sometimes viewed as a defensive sector in uncertain times.
- 03/07/2022
|
Why Doximity Stock Jumped 35% in February
- Investors were happy with the third-quarter earnings report.
- 03/07/2022
|
5 Unstoppable Trends to Invest $10,000 in Right Now
- Don't overlook these potentially huge tech trends.
- 03/02/2022
|
Scared of the Bear? Buy These 3 Healthcare Stocks
- Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.
- 02/18/2022
|
2 Explosive Growth Stocks to Buy in 2022 and Beyond
- These two companies are unsung heroes in their markets, and that could mean they are undervalued today.
- 02/17/2022
|
3 Reasons to Buy Doximity in 2022 and Never Sell
- Patient investors who buy this unique healthcare stock now could see market-beating returns.
- 02/14/2022
|
1 Growth Stock's Dominant Grip Just Got Stronger
- Doximity announced financial results that make its long-term future look bright.
- 02/12/2022
|
2 Growth Stocks To Hold for the Next 10 Years
- These two fast-growing tech stocks deserve a spot on your next buy list.
- 02/10/2022
|
Why Doximity Stock Soared Today
- Advertisers are flocking to the social-media network for doctors.
- 02/09/2022
|
Doximity's growth shows healthcare is finally making the leap to digital, says CEO Jeff Tangney
- Jeff Tangney, Doximity co-founder and CEO, joins 'TechCheck' to discuss the company's quarterly earnings results, potential opportunities for growth and more.
- 02/09/2022
|
Doximity, Inc. (DOCS) CEO Jeff Tangney on Q3 2022 Results - Earnings Call Transcript
- Doximity, Inc. (DOCS) CEO Jeff Tangney on Q3 2022 Results - Earnings Call Transcript
- 02/08/2022
|
Doximity (DOCS) Stock: Why The Price Increased After Hours
- The stock price of Doximity, Inc. (NYSE: DOCS) increased by 8.35% after hours. This is why it happened.
- 02/08/2022
|
Top 5 IPOs of 2021
- Digital World Acquisition, ZIM Integrated Shipping Services, Adagio Therapeutics, Roblox, and Doximity saw the largest percentage increase in stock price since initial listing.
- 02/04/2022
|
Telehealth Stocks Suffered Severe Growing Pains in Past Year
- At the height of the pandemic, telehealth stocks became all the rage as investors concluded that virtual visits would take off since in-person consultations with a physician would be too risky.
- 02/03/2022
|
2 Green Flags and 2 Red Flags for Doximity Stock
- Its future is promising, but there are still a few obstacles to overcome.
- 02/02/2022
|
Bargain Shopping? 2 Growth Stocks Down 50% to 58% to Buy in 2022
- These two industry leaders have fallen far off their all-time highs, and now might be the perfect time to invest.
- 01/30/2022
|
My Top Growth Stock to Buy on Sale for 2022
- Doximity has a dominant hold on this lucrative niche.
- 01/27/2022
|
Doximity to Release Fiscal 2022 Third Quarter Results on February 8, 2022
- SAN FRANCISCO, Jan. 18, 2022/ /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS) will announce financial results for its third quarter which ended December 31, 2021 after market close on February 8, 2022. Doximity will host a conference call and webcast that day at 2:00 p.m.
- 01/18/2022
|
This Monster Growth Stock Could Make You Richer in 2022 (and Beyond)
- Doximity has cultivated a strong brand name among healthcare professionals.
- 01/14/2022
|
Why Doximity Stock Plummeted 26% in December
- It got too high, too fast.
- 01/07/2022
|
TVTY or DOCS: Which Is the Better Value Stock Right Now?
- TVTY vs. DOCS: Which Stock Is the Better Value Option?
- 01/04/2022
|
My Top Tech IPO to Buy in January
- This social media app has everything going right for it.
- 01/04/2022
|
Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
- These two stocks could provide life-changing returns in 10 years.
- 12/29/2021
|
These were the 10 best performing IPOs of 2021 amid a record year for stock market debuts
- Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.
- 12/15/2021
|
Top 5 IPOs of 2021
- Digital World Acquisition, ZIM Integrated Shipping Services, Adagio Therapeutics, Roblox, and Doximity saw the largest percentage increase in stock price since initial listing.
- 12/15/2021
|
Doximity Inc: Leading A New Era In Digital Doctoring
- Doximity works on a subscription basis by offering 3 key solutions: marketing, hiring/ HR services, and telehealth.
- 11/24/2021
|
Over 80% of U.S. physicians are active members of our platform, says Doximity CEO
- Jeff Tangney, Doximity CEO, joins 'TechCheck' to discuss the company's Q2 earnings results where Doximity saw an 8% beat on the top line.
- 11/10/2021
|
Doximity, Inc. (DOCS) CEO Jeffrey Tangney on Q2 2022 Results - Earnings Call Transcript
- Doximity, Inc. (DOCS) CEO Jeffrey Tangney on Q2 2022 Results - Earnings Call Transcript
- 11/09/2021
|
This Healthcare Stock Has a Huge Reach and Massive Revenue Growth Potential
- Amazing market penetration and untapped revenue potential make a nice combination.
- 11/08/2021
|
5 Large-Cap Stocks Likely to Win Big on Earnings Next Week
- Five large-cap (market capital > $10 billion) stocks will report earnings results next week. These are: DHI, RNG, DOCS, DIS and AFRM.
- 11/05/2021
|
Stock Market Hits Resistance As Yields Rise; Microsoft, Nvidia At Key levels, Doximity Tumbles
- Stock market hits resistance as yields keep rising; Microsoft, Nvidia at key levels; Doximity tumbles. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 10/08/2021
|
Up 68% from Its IPO, Is Doximity Still Worth Buying?
- Doximity has seen tremendous share price growth since its IPO, and if it succeeds in expanding its market opportunity, this could continue.
- 09/28/2021
|
2 Top Telehealth Stocks to Buy for the Long Haul
- The healthcare industry is changing. Investors should adapt.
- 09/26/2021
|
Why Doximity Stock Soared 49% in August
- Sales doubled in the most recent quarter.
- 09/03/2021
|
Why Doximity Plunged Nearly 13% Today
- An analyst only stated what had become relatively obvious about this young stock.
- 08/26/2021
|
Doximity Announces 2021-2022 Residency Navigator
- SAN FRANCISCO, Aug. 26, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for medical professionals, today announced the release of its 2021-2022 Residency Navigator tool. Over 90% of graduating U.S. medical students join Doximity to use tools including Residency Navigator before earning their medical degree.
- 08/26/2021
|
3 Unstoppable Healthcare Stocks to Buy Now
- Find out why these companies are dominating in the niches they created.
- 08/25/2021
|
Will Telehealth Stocks Thrive After COVID?
- Internet healthcare companies have seen their revenue skyrocket during the pandemic. What will the future bring?
- 08/24/2021
|
Why Doximity Stock Surged on Monday
- The networking and productivity platform for doctors is riding a wave of positive investor sentiment.
- 08/23/2021
|
Doximity to Participate in a Virtual Fireside Chat at Morgan Stanley's 19th Annual Global Healthcare Conference
- SAN FRANCISCO, Aug. 23, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS) today announced that Anna Bryson, CFO, will participate in a virtual fireside chat at Morgan Stanley's 19th Annual Global Healthcare Conference on Thursday, Sept. 9, 2021, at 5:00 p.m.
- 08/23/2021
|
Wall Street Thinks You Can't Lose With This Healthcare Stock
- Every analyst's target is higher than the current price.
- 08/19/2021
|
Jim Cramer says Doximity and Upstart are the two 'star' IPOs of 2021
- Doximity and Upstart are the two "star" initial public offerings of this year, according to "Mad Money" host Jim Cramer.
- 08/12/2021
|
Here's Why Doximity Stock Is Surging Today
- The networking platform for healthcare professionals keeps exceeding expectations.
- 08/11/2021
|
Doximity, Inc. (DOCS) CEO Jeff Tangney on Q2 2021 Results - Earnings Call Transcript
- Doximity, Inc. (DOCS) CEO Jeff Tangney on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Doximity shares jump after digital health company says revenue doubled in first report since IPO
- Doximity said revenue in the fiscal first quarter climbed to $72.7 million from $36.4 million a year earlier.
- 08/10/2021
|
Doximity Announces Fiscal 2022 First Quarter Financial Results
- SAN FRANCISCO, Aug. 10, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2022 first quarter ended June 30, 2021. "We're pleased to report strong financial results in our first quarter as a public company -- triple digit revenue growth and record profit margins.
- 08/10/2021
|
Should You Invest in Recent Healthcare IPO Doximity?
- This company is helping physicians improve their productivity with digital tools and a professional network.
- 08/06/2021
|
Is This New Healthcare IPO Worth the Hype?
- Doximity went public last month, and it is already trading at a steep price tag.
- 07/29/2021
|
1 Recent Healthcare IPO to Put on Your Radar
- This app for healthcare professionals could be an interesting investment.
- 07/24/2021
|
Better Healthcare Stock: Teladoc vs. Doximity
- Teladoc Health was the first mover, but it's no longer top dog by some standards.
- 07/24/2021
|
Doximity to Release Fiscal 2022 First Quarter Results on August 10, 2021
- SAN FRANCISCO, July 20, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS) will announce financial results for its first quarter which ended June 30, 2021 after market close on August 10, 2021. Doximity will host a conference call and webcast that day at 2:00 p.m.
- 07/20/2021
|
I'm Buying Doximity, But Not For A While
- Doximity, sometimes known as the LinkedIn for doctors, IPO'd recently, and the share price jumped. Doximity has a high-quality business model and offers lots of products and services to doctors, which is why I am interested.
- 07/02/2021
|
7 Stocks to Sell as You Head Into July 2021
- These stocks to sell have stretched valuation, but their fundamentals are robust and these stocks are worth accumulating on a correction. The post 7 Stocks to Sell as You Head Into July 2021 appeared first on InvestorPlace.
- 07/02/2021
|
After Popping 115% Since Its IPO, Doximity Stock Could Keep Rising
- Some 10,000 physicians in its network are betting an average of $24,000 apiece on Doximity stock. If it can sustain expectations-beating growth, those MDs are making a smart bet.
- 06/28/2021
|
Doximity: Potential Teladoc Killer
- As the LinkedIn for doctors, Doximity has massive potential to be a dominant player in the telehealth market. Its main value proposition is its network of medical professionals. Teladoc's struggle is Doximity's opportunity.
- 06/27/2021
|
Doximity CEO ignored Silicon Valley wisdom and built a $10 billion health-tech company
- Doximity CEO Jeff Tangney became the latest tech billionaire this week after taking Doximity public on the New York Stock Exchange.
- 06/27/2021
|
U.S. IPO Weekly Recap: Doximity Pops More Than 100% In A 16 IPO Week
- 16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity, which soared 104% in its debut. The week's IPOs were joined by four SPACs, as well as one postponement, Chinese social networking platform Soulgate.
- 06/25/2021
|
Venture capital firms are big winners in latest IPOs
- CNBC's Ari Levy explains how four Silicon Valley firms were the winners as Confluent and Doximity went public Thursday.
- 06/25/2021
|
Doximity IPO: 16 Things to Know About DOCS Stock After Its 103% Debut
- Doximity (DOCS) stock is retreating on Friday after the company saw its shares rocket higher with its initial public offering (IPO). The post Doximity IPO: 16 Things to Know About DOCS Stock After Its 103% Debut appeared first on InvestorPlace.
- 06/25/2021
|
Doximity Blows Away IPO Goal On First Day Of NYSE Trading
- Healthcare technology platform Doximity Inc. and an investor raised $606 million after pricing an initial public offering above the marketed range, according to a company statement. Doximity was originally shooting for a $100 million initial public offering (IPO) in its May 28 filing with the Securities and Exchange Commission for the ticker symbol DOCS.
- 06/24/2021
|
Digital Medical Networking Platform Doximity Makes NYSE Debut
- Online medical networking platform Doximity has launched its IPO on the New York Stock Exchange with shares opening at more than $41. According to Doximity's Chief Financial Officer Anna Bryson, digital medicine has been "under indexed" for years, but as COVID-19 spread, more healthcare professionals started to invest in digital care.
- 06/24/2021
|
Four Silicon Valley VC firms notched billion-dollar IPO wins on Thursday
- Benchmark and Index Ventures are the biggest winners from Confluent's IPO, while Emergence Capital and InterWest Partners are the top investors in Doximity.
- 06/24/2021
|
Doximity surges 69% in NYSE debut after IPO values health-tech company at $4.6 billion
- Doximity, an 11-year old online network for medical professionals, went public after increasing revenue 77% in the latest fiscal year to over $200 million.
- 06/24/2021
|
Doximity CEO on physician social network going public: "Our mission is to help doctors be more produ
- CNBC TechCheck's Deirdre Bosa chats with Doximity Co-Founder and CEO Jeff Tangney as the physician social network platform goes public this morning, and allocates 15% of its IPO to doctors.
- 06/24/2021
|
6 Companies Are Making Their Trading Debuts. What Investors Need to Know.
- The IPO tidal wave continued Thursday, with a mix of healthcare and technology startups making their trading debut.
- 06/24/2021
|
HealthCare Provider Doximity Prices Upsized IPO At $26/Share; Trading Begins Today
- Doximity, Inc (NYSE: DOCS) priced 23.3 million shares at $26 per share in its initial public offering, for estimated gross proceeds are $494.3 million. The healthcare platform previously marketed the IPO at the range of $20 - $23, Bloomberg reports.
- 06/24/2021
|
Doximity Announces Pricing of Initial Public Offering
- SAN FRANCISCO, June 23, 2021 /PRNewswire/ -- Doximity, Inc. ("Doximity") (NYSE: DOCS) today announced the pricing of its initial public offering of 23,300,000 shares of its Class A common stock at a price to the public of $26.00 per share. The offering consists of 19,010,750 shares of Class A common stock being sold by Doximity and 4,289,250 shares of Class A common stock being sold by an existing stockholder.
- 06/23/2021
|
